Suppr超能文献

内镜超声定义的淋巴结转移计数对食管癌的预后意义。

Prognostic significance of the endoscopic ultrasound defined lymph node metastasis count in esophageal cancer.

机构信息

South East Wales Cancer Network, Department of General and Upper GI Surgery, University Hospital of Wales, Cardiff, UK.

出版信息

Dis Esophagus. 2010 Nov;23(8):652-9. doi: 10.1111/j.1442-2050.2010.01072.x.

Abstract

The key prognostic factor which predicts outcome after esophagectomy for cancer is the number of malignant lymph node metastases, but data regarding the accuracy of endoscopic ultrasound (EUS) in determining and predicting the metastatic lymph node count preoperatively are limited. The aim of this study was to assess the prognostic significance of EUS defined lymph node metastasis count (eLNMC) in patients diagnosed with esophageal cancer. Two hundred and sixty-seven consecutive patients (median age 63 years, 187 months) underwent specialist EUS followed by stage directed multidisciplinary treatment (183 esophagectomy [64 neoadjuvant chemotherapy, 19 neoadjuvant chemoradiotherapy], 79 definitive chemoradiotherapy, and 5 palliative therapy). The eLNMC was subdivided into four groups (0, 1, 2 to 4, >4) and the primary measure of outcome was survival. Survival was related to EUS tumor (T) stage (P < 0.0001), EUS node (N) stage (P < 0.0001), EUS tumor length (p < 0.0001), and eLNMC (P < 0.0001). Multivariable analysis revealed EUS tumor length (hazard ratio [HR] 1.071, 95% CI 1.008-1.138, P= 0.027) and eLNMC (HR 1.302, 95% CI 1.133-1.496, P= 0.0001) to be significantly and independently associated with survival. Median and 2-year survival for patients with 0, 1, 2-4, and >4 lymph node metastases were: 44 months and 71%, 36 months and 59%, 24 months and 50%, and 17 months and 32%, respectively. The total number of EUS defined lymph node metastases was an important and significant prognostic indicator.

摘要

影响食管癌患者手术后预后的关键预测因素是恶性淋巴结转移的数量,但关于内镜超声(EUS)术前确定和预测转移性淋巴结计数的准确性的数据有限。本研究旨在评估 EUS 定义的淋巴结转移计数(eLNMC)在诊断为食管癌患者中的预后意义。267 例连续患者(中位年龄 63 岁,187 个月)接受了专科 EUS 检查,然后进行了分期导向的多学科治疗(183 例食管癌切除术[64 例新辅助化疗,19 例新辅助放化疗],79 例确定性放化疗和 5 例姑息性治疗)。eLNMC 分为四组(0、1、2-4、>4),主要的预后指标是生存。生存与 EUS 肿瘤(T)分期(P < 0.0001)、EUS 淋巴结(N)分期(P < 0.0001)、EUS 肿瘤长度(p < 0.0001)和 eLNMC(P < 0.0001)相关。多变量分析显示,EUS 肿瘤长度(危险比[HR] 1.071,95%置信区间 1.008-1.138,P=0.027)和 eLNMC(HR 1.302,95%置信区间 1.133-1.496,P=0.0001)与生存显著相关。0、1、2-4 和>4 个淋巴结转移的患者的中位生存期和 2 年生存率分别为:44 个月和 71%、36 个月和 59%、24 个月和 50%、17 个月和 32%。EUS 定义的淋巴结转移总数是一个重要且显著的预后指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验